TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16523022

Group type: EXPERIMENTAL
Intervention: iPAT with acceleration factor of 2
Number of subjects: 24

Group type: COMPARATOR
Intervention: iPAT with acceleration factor of 4
Number of subjects: 24
Study: 12778045

Group type: EXPERIMENTAL
Intervention: Well-controlled feeding approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral counseling studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research diets prepared by dietitians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy requirement adjustments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethical treatment and motivation of participants
Number of subjects: 0
Study: 11099449

Group type: EXPERIMENTAL
Intervention: Stroke patients with central arm paresis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Stroke patients with somatosensory deficits
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Stroke patients with ideomotor apraxia
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23
Study: 8780817

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Alternating therapy (ZDV/ddI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) therapy (monotherapy or alternating)
Number of subjects: 46
Study: 1600993

Group type: EXPERIMENTAL
Intervention: gallopamil 150 mg daily for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: nifedipine 60 mg daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 6541198

Group type: EXPERIMENTAL
Intervention: Regimen A: rifampin 600 mg twice weekly, prothionamide 500 mg, and dapsone (DDS) 100 mg daily for six months, followed by 100 mg DDS daily for another six months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regimen B: identical to Regimen A but without prothionamide
Number of subjects: 20
Study: 29710289

Group type: EXPERIMENTAL
Intervention: Medisafe smartphone app
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 412
Study: 27404902

Group type: EXPERIMENTAL
Intervention: Bali Yoga Program for Breast Cancer Patients (BYP‐BC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait list control group (standard care)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 101
Study: 24793093

Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine (IV BUP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intranasal buprenorphine (IN BUP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22740213

Group type: EXPERIMENTAL
Intervention: Mini Nutrition Assessment (MNA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mini Nutrition Assessment Short-Form (MNASF)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 103
Study: 19680659

Group type: EXPERIMENTAL
Intervention: 900 ml of low-density barium sulphate (LDB) (group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 900 ml of low-density barium sulphate (LDB) (groups C, D, E)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No oral contrast agent (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 900 ml of water (group B)
Number of subjects: 90
Study: 18559644

Group type: COMPARATOR
Intervention: 75 mg oral oseltamivir every 24 h (group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 75 mg oseltamivir every 48 h combined with 500 mg probenecid four times a day (group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3)
Number of subjects: 48
Study: 15984725

Group type: EXPERIMENTAL
Intervention: Short form with 70 subitems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long form with 140 subitems
Number of subjects: 0
Study: 12215687

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.2 mg/ml
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/ml
Number of subjects: 83

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) 0.2 mg/ml and 0.4 mg/ml
Number of subjects: 83
Study: 10667741

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 245

Group type: COMPARATOR
Intervention: Haloperidol or another conventional antipsychotic
Number of subjects: 245
Study: 7541769

Group type: EXPERIMENTAL
Intervention: Low dose GH (0.125 IU/kg/week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose GH (0.5 IU/kg/week)
Number of subjects: 12
Study: 2116083

Group type: EXPERIMENTAL
Intervention: UFT (400 mg/day for 6 months)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (non-medication group)
Number of subjects: 111
Study: 877639

Group type: EXPERIMENTAL
Intervention: Mucoadhesive foam containing a local anesthetic plus a corticosteroid
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spray containing a local anesthetic plus an antiseptic agent
Number of subjects: 100
Study: 31111123

Group type: EXPERIMENTAL
Intervention: InGaAsP followed by subgingival debridement (SD) and Er,Cr:YSGG laser
Number of subjects: 42

Group type: COMPARATOR
Intervention: Subgingival debridement (SD) alone
Number of subjects: 42
Study: 28333029

Group type: EXPERIMENTAL
Intervention: Diluted hyaluronidase (8 IU/mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal hyaluronidase (80 IU/mL)
Number of subjects: 22
Study: 25843912

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of 5-aminolevulinic acid (5-ALA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 20 mg/kg of 5-aminolevulinic acid (5-ALA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional endoscopic diagnosis
Number of subjects: 62
Study: 23816561

Group type: EXPERIMENTAL
Intervention: Sinusoidal chronomodulated infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Flat intermittent constant rate infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Number of subjects: 124
Study: 21356150

Group type: EXPERIMENTAL
Intervention: Six servings of low glycaemic index (LGI) foods daily
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Eight servings of low glycaemic index (LGI) foods daily
Number of subjects: 35
Study: 19081704

Group type: EXPERIMENTAL
Intervention: Communication training for physicians
Number of subjects: 0
Study: 17405995

Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard chemotherapy, 87% received cyclophosphamide, methotrexate, and 5-fluorouracil; 11% received anthracycline-containing regimens)
Number of subjects: 1991

Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard chemotherapy)
Number of subjects: 1991
Study: 10821994

Group type: EXPERIMENTAL
Intervention: Intact order/original wording (n=148)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Intact order/revised wording (n=183)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Split order/original wording (n=192)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Split order/revised wording (n=166)
Number of subjects: 688
Study: 8787073

Group type: EXPERIMENTAL
Intervention: Drug (specific drug not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1899746

Group type: EXPERIMENTAL
Intervention: MR imaging with a body coil
Number of subjects: 26
Study: 6131857

Group type: EXPERIMENTAL
Intervention: 2 x 150 mg ranitidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 x 400 mg cimetidine
Number of subjects: 60
Study: 31067347

Group type: EXPERIMENTAL
Intervention: Intervention arm (screening with prostate-specific antigen and digital rectal examination)
Number of subjects: 76383

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 76383
Study: 29318868

Group type: EXPERIMENTAL
Intervention: medium renewed on day 3
Number of subjects: 82

Group type: COMPARATOR
Intervention: medium not renewed on day 3
Number of subjects: 82
Study: 27100364

Group type: EXPERIMENTAL
Intervention: Childhood negative emotionality (NE)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Problematic alcohol use
Number of subjects: 160
Study: 25146732

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiofrequency current (RFC) ablation
Number of subjects: 0
Study: 22966034

Group type: EXPERIMENTAL
Intervention: Behavioral techniques delivered over 1 to 3 individual nurse consultations at infant age 8 to 10 months
Number of subjects: 326

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326
Study: 19927136

Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Pill count
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both MEMS and pill count
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: MEMS
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 228
Study: 17873682

Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation (LFR-TMS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-frequency left-sided transcranial magnetic stimulation (HFL-TMS)
Number of subjects: 26
Study: 15957843

Group type: EXPERIMENTAL
Intervention: Aiyishu Injection (AYSI), 50 ml by intrathoracic and another 50 ml by intravenous injection, repeated after 3 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemotherapeutic agent or interleukin-2 (IL-2)
Number of subjects: 60
Study: 12048138

Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment for 3 months
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment
Number of subjects: 853
Study: 9924649

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 0
Study: 7573262

Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride, 30 mg per day
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 2253535

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg four times a day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice a day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cimetidine (both dosages)
Number of subjects: 80
Study: 31219671

Group type: EXPERIMENTAL
Intervention: Compact, cost-effective education program (CEPT1) - 3 sessions of 90 minutes each, with one session per week, containing five short videos.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group - extensive education program delivered through 45-minute PowerPoint lectures, one class every 3 months.
Number of subjects: 62
Study: 29057618

Group type: EXPERIMENTAL
Intervention: Bococizumab 0.25 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Bococizumab 1 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Bococizumab 3 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Bococizumab 6 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Bococizumab 6 mg/kg (all three doses)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 26228480

Group type: EXPERIMENTAL
Intervention: Bolstered usual care plus a family-level economic strengthening intervention (Suubi-Maka treatment arm)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual care (counseling, school uniforms, school lunch, notebooks, and textbooks) with mentorship (control condition)
Number of subjects: 346
Study: 24992418

Group type: EXPERIMENTAL
Intervention: Care influenced by the surgical Apgar score (SAS)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 143
Study: 21292625

Group type: EXPERIMENTAL
Intervention: Drug Burden Index (DBI)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Beers criteria
Number of subjects: 115
Study: 21158218

Group type: EXPERIMENTAL
Intervention: Intensive exercise program (90 minutes/day, two days/week for 12 weeks) with lifestyle modification counseling
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional counseling at an out-patient clinic
Number of subjects: 38
Study: 17914954

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg for 2 days and 1 hour before the test
Number of subjects: 13

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 13
Study: 16199834

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 548
Study: 11809341

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone (Livial) daily for 12 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo daily for 12 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Comparison between tibolone and placebo
Number of subjects: 85
Study: 10052765

Group type: COMPARATOR
Intervention: Scaling and root planing alone (S)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 25% tetracycline fibers (S+Tet)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 2% minocycline gel (S+Min)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 25% metronidazole gel (S+Met)
Number of subjects: 79
Study: 7485940

Group type: EXPERIMENTAL
Intervention: Predeposited autologous blood transfusion (PABT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra/postoperative blood salvage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of blood salvage and three units of PABT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost comparison of blood salvage
Number of subjects: 0
Study: 1967729

Group type: COMPARATOR
Intervention: Outpatient care
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 141
Study: 7422399

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) 100 mg at bedtime for the last few weeks of pregnancy
Number of subjects: 2863

Group type: COMPARATOR
Intervention: Control group (no phenobarbital treatment)
Number of subjects: 2863

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) group
Number of subjects: 2863

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2863

Group type: EXPERIMENTAL
Intervention: Children with moderate or marked jaundice (bilirubin > 12 mg/dl)
Number of subjects: 2863
Study: 31526875

Group type: EXPERIMENTAL
Intervention: CR4056 (100 mg bid for women; 200 mg bid for men)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: CR4056 in metabolic OA phenotype (BMI ≥ 27.5 kg/m2, N = 156)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: CR4056 in neuropathic or inflammatory phenotype
Number of subjects: 213
Study: 30969174

Group type: EXPERIMENTAL
Intervention: Mindfulness app
Number of subjects: 90

Group type: COMPARATOR
Intervention: Behavioral self-monitoring electronic diary (e-diary)
Number of subjects: 90
Study: 28283195

Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174
Study: 26016861

Group type: COMPARATOR
Intervention: High egg (HE) meal (150 g scrambled whole eggs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low egg (LE) meal (75 g scrambled whole eggs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control meal (no egg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High egg (HE) meal
Number of subjects: 16
Study: 23958768

Group type: EXPERIMENTAL
Intervention: Computerized decision support system for ADHD diagnosis and treatment guidelines.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no computerized decision support system).
Number of subjects: 84
Study: 20884642

Group type: EXPERIMENTAL
Intervention: Screening for PND using the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Clinical assessment for PND screening (Control)
Number of subjects: 462
Study: 19263929

Group type: EXPERIMENTAL
Intervention: Computer-based fire safety training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 17503435

Group type: EXPERIMENTAL
Intervention: Health-related support groups
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Support group perception
Number of subjects: 1844

Group type: EXPERIMENTAL
Intervention: Physician recommendation for support groups
Number of subjects: 1844
Study: 15302282

Group type: EXPERIMENTAL
Intervention: GnRH antagonist + recombinant LH (75 IU/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: GnRH antagonist alone (C)
Number of subjects: 42
Study: 11536410

Group type: EXPERIMENTAL
Intervention: Velocity-dependent method (16-18 mL of gadolinium)
Number of subjects: 54

Group type: COMPARATOR
Intervention: High-dose method (38 mL of gadolinium)
Number of subjects: 54
Study: 9491873

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol (E2), 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle) for 12 months, then E2, 2 mg daily, combined with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for 3 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study: 8061720

Group type: EXPERIMENTAL
Intervention: Pattern analysis method for assessing successful weight reduction
Number of subjects: 0
Study: 3380504

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with meperidine by pump
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intramuscular injection of meperidine
Number of subjects: 130
Study: 30548928

Group type: EXPERIMENTAL
Intervention: Multimedia surgical care tour (4 educational videos and automated reminders to take medications)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (sham platform)
Number of subjects: 121
Study: 28545493

Group type: EXPERIMENTAL
Intervention: Once daily testing with standard feedback (glucose values reported immediately)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once daily testing with enhanced patient feedback (glucose values reported immediately plus automated tailored feedback messaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No testing
Number of subjects: 0
Study: 25437509

Group type: EXPERIMENTAL
Intervention: Supervised therapy (n=89)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Home-based therapy (n=36)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Supervised therapy (high performers, n=70)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Home-based therapy (high performers, n=38)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Supervised therapy and Home-based therapy (WOMAC subscales)
Number of subjects: 233
Study: 22789392

Group type: EXPERIMENTAL
Intervention: interpositional non-ceramic hydroxylapatite bone graft
Number of subjects: 12

Group type: COMPARATOR
Intervention: interpositional intra-oral autogenous bone graft
Number of subjects: 12
Study: 21482437

Group type: EXPERIMENTAL
Intervention: Family psychoeducational intervention (FPEI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance focused intervention (TAFI)
Number of subjects: 0
Study: 19591067

Group type: EXPERIMENTAL
Intervention: Oral Naltrexone (NTX) treatment 3 times per week for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Voucher-based incentives (VBI) for attendance
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Motivational counseling (MI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Study medication (NTX)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Breath alcohol testing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Reporting alcohol use
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall benefits reported by patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall benefits reported by providers
Number of subjects: 90
Study: 16406224

Group type: EXPERIMENTAL
Intervention: DTPa-IPV booster vaccine
Number of subjects: 0
Study: 15291288

Group type: EXPERIMENTAL
Intervention: Cyclic nonplatinum chemotherapy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Transfusions
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 273
Study: 11702325

Group type: EXPERIMENTAL
Intervention: Propofol (5‐10 mg/kg/h) and remifentanil (0.125‐1.0 microgram/kg/min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane (1.0‐1.5 MAC) and remifentanil (0.125‐1.0 microgram/kg/min)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 9389861

Group type: EXPERIMENTAL
Intervention: alfentanil 20 micrograms kg‐1, propofol 2.5 mg kg‐1 and vecuronium 0.1 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: thiopentone 5 mg kg‐1 and suxamethonium 1 mg kg‐1
Number of subjects: 60
Study: 7932942

Group type: EXPERIMENTAL
Intervention: High cognitive anxiety with increasing heart rate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High cognitive anxiety with decreasing heart rate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low cognitive anxiety
Number of subjects: 8
Study: 3286173

Group type: EXPERIMENTAL
Intervention: PPA 75 mg SR
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: PPA SR 75 mg with caffeine 200 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 28707491

Group type: EXPERIMENTAL
Intervention: Omega-3 supplement (1g fish oil)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (free of oil)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 27718414

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavior therapy (ABBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 0
Study: 26571323

Group type: EXPERIMENTAL
Intervention: Preoperative forced-air warming for 20 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no warming)
Number of subjects: 50
Study: 24156397

Group type: EXPERIMENTAL
Intervention: One-time contact-based educational intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Multimodal undergraduate psychiatry course
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Stigma towards mental illness
Number of subjects: 111